DiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 3.6%

DiaMedica Therapeutics Inc. (NASDAQ:DMAC)’s stock price fell 3.6% during mid-day trading on Tuesday . The stock traded as low as $2.41 and last traded at $2.42. 5,238 shares traded hands during trading, a decline of 87% from the average session volume of 41,772 shares. The stock had previously closed at $2.51.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Oppenheimer reissued an “outperform” rating and set a $6.00 price objective (down previously from $7.00) on shares of DiaMedica Therapeutics in a report on Thursday, March 21st. Craig Hallum cut their price target on DiaMedica Therapeutics from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, March 21st.

DiaMedica Therapeutics Trading Down 3.6 %

The company’s 50-day simple moving average is $2.81 and its 200-day simple moving average is $2.70. The stock has a market capitalization of $91.86 million, a price-to-earnings ratio of -3.90 and a beta of 1.69.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.14) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.14). On average, equities research analysts expect that DiaMedica Therapeutics Inc. will post -0.69 earnings per share for the current fiscal year.

Institutional Trading of DiaMedica Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Stonebridge Capital Advisors LLC acquired a new stake in DiaMedica Therapeutics during the 3rd quarter worth about $52,000. Paragon Associates & Paragon Associates II Joint Venture lifted its stake in shares of DiaMedica Therapeutics by 6.4% in the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock valued at $1,420,000 after purchasing an additional 30,000 shares during the period. Finally, Avantax Advisory Services Inc. bought a new stake in shares of DiaMedica Therapeutics during the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.